Overview: Liver Kidney Microsomal Antibody TestIntroduction: The Liver Kidney Microsomal Antibody Test detects LKM antibodies to diagnose autoimmune hepatitis, causing liver dysfunction or pain. Following 2023 AASLD guidelines, it uses immunofluorescence assay for high specificity, supporting liver screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected autoimmune hepatitis.
Other Names: LKM Antibody Assay, Autoimmune Hepatitis Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: LKM antibody testing began in the 1970s with autoimmune hepatitis research. Immunofluorescence methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects LKM antibodies to diagnose autoimmune hepatitis, guides treatment, and evaluates patients with liver dysfunction or pain.
Test Parameters: 1. LKM Antibodies
Pretest Condition: No fasting required. Collect serum or saliva. Report history of liver dysfunction, pain, or jaundice.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document liver dysfunction, pain, jaundice, or family history of autoimmune diseases. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, autoimmune hepatitis implications, and risks of blood or saliva collection.
Procedural Considerations: Uses immunofluorescence assay to detect LKM antibodies in serum or saliva. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for autoimmune hepatitis diagnosis.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Insufficient sample volume may reduce accuracy.
Clinical Significance: Positive LKM antibodies confirm autoimmune hepatitis, guiding immunosuppressive therapy. Negative results may require further autoimmune testing.
Specialist Consultation: Consult a hepatologist for result interpretation and treatment planning.
Additional Supporting Tests: ANA, SMA, or liver biopsy to confirm autoimmune hepatitis diagnosis.
Test Limitations: Not specific to autoimmune hepatitis; other liver diseases may produce LKM antibodies. Clinical correlation is needed.
References: AASLD Hepatitis Guidelines, 2023; Hepatology, Manns MP, 2022.
